...for antiviral activity. Repurposing candidates include at least two that inhibit BRD2/BRD4: apabetalone (RVX-208) from Resverlogix Corp....

...and Complexa Inc. has CXA-10, which also regulates NF-κB, in Phase II for renal damage. Resverlogix Corp....

...Bardoxolone methyl Treat chronic kidney disease (CKD) caused by Alport syndrome Phase III data 2H19 Resverlogix Corp....

...2H19 RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) Talicia (RHB-105) Helicobacter pylori infection Submit NDA 1H19 Resverlogix Corp....

.../ Novartis AG (NYSE:NVS; SIX:NOVN) AVXS-101 Spinal muscular atrophy (SMA) type 1 Submit BLA 2H18 Resverlogix Corp....

...Inc. (NASDAQ:REGN) / Sanofi (Euronext:SAN; NYSE:SNY) Cemiplimab Cutaneous squamous cell carcinoma Complete rolling BLA 1Q18 Resverlogix Corp....

...On Oct. 13, Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested...
...0.08 of a share. Prior to the placement, Hepalink held a 13% equity stake in Resverlogix...
...disease (ESRD) by year end (see BioCentury, May 4, 2015 ). Resverlogix Corp. (TSX:RVX), Calgary, Alberta Allison Johnson apabetalone RVX-208 RVX000222 Resverlogix Corp. Shenzhen...

...0.08 of a share. Prior to the placement, Hepalink held a 13% equity stake in Resverlogix...
...would have held a 14% stake. The new offering gives Hepalink a 43% stake in Resverlogix...
...BioCentury Extra, April 27, 2015) . Resverlogix lost C$0.20 (11%) to C$1.56 on Friday. Jaime De Leon apabetalone RVX-208 RVX000222 Resverlogix Corp. Shenzhen...

...Alzheimer’s disease, and more than ten other companies are testing pan-HDAC inhibitors in non-oncology indications. Resverlogix Corp....
...Inc. (NYSE:PFE), New York, N.Y. Quimatryx S.L., San Sebastian, Spain Regenacy Pharmaceuticals LLC, Boston, Mass. Resverlogix Corp....

...is an inhibitor of the BET family of bromodomain-containing proteins, including bromodomain containing 4 (BRD4). Resverlogix Corp....
...in lipid concentrations Status: Phase III ongoing Milestone: Complete Phase III enrollment (year end 2017) Julian Zhu apabetalone RVX-208 RVX000222 Resverlogix Corp. Apolipoprotein...